Alert-HF: Early Detection and Intervention on Atrial Fibrillation in Heart Failure Patients (Alert-HF)
The goal of this clinical trial is to learn if using remote heart rhythm monitoring strategies can reduce unplanned cardiac care utilization and improve health-related quality of life in adults with heart failure (HF). It focuses on adults with heart failure who have no history of an irregular heartbeat called atrial fibrillation (AF) and do not have an existing pacemaker or implantable defibrillator.
The main questions the trial aims to answer are:
- Does a continuous rhythm monitor placed under the skin or a patient-driven portable home device decrease unplanned cardiac care utilization?
- Do these rhythm monitoring strategies influence therapeutic management?
- Do these rhythm monitoring strategies improve patient-reported quality of life and overall survival?
Researchers will compare two monitoring groups to a standard care group over an 18-month period to see which approach works best in heart failure treatment
Participants will:
- either have a small heart monitor placed under their chest skin for heart rhythm observation (arm 1), use a handheld device to take regular heart recordings at home (arm 2) or follow standard care (arm 3) for a period of 18 months
- Answer a health survey at the start of the study and after 18 months of follow-up.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Dr. Schuuring, MD PhD
- Número de teléfono: 0031534872000
- Correo electrónico: mark.schuuring@utwente.nl
Ubicaciones de estudio
-
-
-
Enschede, Países Bajos, 7512 KZ
- Medisch Spectrum Twente
-
Contacto:
- Dr Schuuring, MD PhD
- Número de teléfono: 0031534872000
- Correo electrónico: mark.schuuring@utwente.nl
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adult patients with HF and no history of documented AF on electrocardiogram (ECG)
Exclusion Criteria:
- Patients with CIED, such as an implantable cardioverter defibrillator (ICD), Cardiac Resynchronization Therapy Defibrillator (CRT-D), or pacemaker.
- Documented AF before inclusion
- Admission to hospices or palliative care
- Inability to communicate in Dutch or English.
- Participant under the age of 18 years old
- Participant is pregnant
- Mental disorders that, according to the treating physician, make participation unsafe
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador activo: Arm 1: Hospital-driven continuous monitoring with an implantable loop recorder
Arm 1: Hospital-driven continuous rhythm monitoring with an implantable loop recorder (ILR) placed subcutaneously in the left pectoral region. |
Hospital-driven continuous monitoring with an implantable loop recorder |
|
Comparador activo: Arm 2: Patient-driven portable ECG monitoring
Patient-driven single-lead portable ECG monitoring in which patients are instructed to send ECG recordings of at least 30 seconds both on a scheduled routine basis and whenever experiencing symptoms suggestive of an arrhytmia. |
Patient-driven portable ECG monitoring |
|
Comparador activo: Arm 3: Usual Care
All patients are treated according to the ESC guidelines (ESC HF 2026). This includes periodic outpatient utilization. |
Usual care |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of unplanned cardiac care utilization
Periodo de tiempo: 18 months
|
Unplanned cardiac healthcare utilization will be assessed through systematic review of patients' medical records. The number of healthcare episodes occurring during the study observation period will be recorded. Each unique healthcare episode will be classified according to the principal setting of care: outpatient clinic, daycare/day-case admission, emergency care without admission, or hospitalization. Both total and stratified care utilization will be reported. An episode will be considered unplanned when healthcare is initiated in response to an acute, unexpected, worsening, or urgent cardiac health problem. Healthcare episodes involving transfers between care settings as part of the same continuous episode will be counted once and classified according to the highest level of care reached, to avoid double counting. |
18 months
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of planned cardiac care utilization
Periodo de tiempo: 18 months
|
Planned healthcare utilization comprises healthcare episodes scheduled or arranged in advance for routine, preventive, diagnostic, therapeutic, monitoring, rehabilitation, or follow-up care. This includes planned hospitalizations, planned daycare/day-case encounters, and planned outpatient clinic visits. |
18 months
|
|
Time from inclusion to first diagnosis of AF
Periodo de tiempo: 18 months
|
The clinical diagnosis of AF by a healthcare professional must be supported by ECG documentation demonstrating AF on a single-lead recording of at least 30 seconds or a standard 12-lead ECG, obtained using the assigned monitoring device or as part of routine clinical care. |
18 months
|
|
The number of participants diagnosed with AF according to the electronic health rercords (EHR)
Periodo de tiempo: 18 months
|
AF diagnosis will be established based on electrocardiographic (ECG) documentation obtained either through the assigned monitoring strategy or as part of routine clinical care, as assessed by a qualified healthcare professional. |
18 months
|
|
Number of AF-related pharmacological and non-pharmacological management changes
Periodo de tiempo: 18 months
|
Pharmacological changes include initiation, discontinuation, dose increase, dose decrease or switching of oral anticoagulants (OAC) and rate- and/or rhythm-control medications, including antiarrhythmic drugs. Non-pharmacological interventions include electrical or pharmacological cardioversion, catheter ablation and AF-related CIED implantation or reprogramming. The number of management changes will be grouped according to the treatment type and type of adjustment. |
18 months
|
|
Number of HF-related pharmacological and non-pharmacological management changes during the study observation period.
Periodo de tiempo: 18 months
|
Pharmacological changes include initiation, discontinuation, dose increase, dose decrease or switching of guideline-directed medical therapy (GDMT), including ARNI/ACEi/ARB, beta-blockers, mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 inhibitors (SGLT2i) and diuretics. Non-pharmacological interventions include HF-related CIED implantation or device reprogramming. The number of management changes will be grouped according to the treatment type and type of adjustment. |
18 months
|
|
Number of overall arrhythmia diagnosis extracted from EHR
Periodo de tiempo: 18 months
|
Number of overall arrhythmia diagnosis |
18 months
|
|
Changes in Quality of life from baseline to 18 months follow-up as assessed by the Quality of life Kansas City Cardiomyopathy Questionnaire
Periodo de tiempo: 18 months
|
The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) will be collected at baseline and 18 months. The scores are represented on a scale from 0 to 100 points, where lower scores represent more severe symptoms and higher scores less or no symptoms. |
18 months
|
|
Change in heart failure-related quality of life from baseline to 18-month follow-up, as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ).
Periodo de tiempo: 18 months
|
The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) will be collected at baseline and 18 months. The scores are represented on a scale from 0 to 100 points, where lower scores represent more severe symptoms and higher scores less or no symptoms. |
18 months
|
|
Changes in overall Quality of Life from baseline to 18 months follow-up as assessed by the EuroQol 5-Dimension 5-Level (EQ-5D-5L)
Periodo de tiempo: 18 months
|
The EQ-5D-5L is a standardized questionnaire assessing health-related quality of life across five dimensions on a score from 1 to 5, with one no problems to a score of five with extreme problems on that domain. This allows for direct comparison between baseline and follow-up. The questionnaire also includes a visual analogue scale (EQ-VAS), ranging from 0 (worst imaginable health) to 100 (best imaginable health), on which participants rate their overall health. Furthermore, responses are used to calculate a health utility index score with values between 0 and 1. 0 indicates life valuation equal to death and one full health. |
18 months
|
|
Mortality
Periodo de tiempo: 18 months
|
Mortality |
18 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA, Ellinor PT, Cheng S, Vasan RS, Lee DS, Wang TJ, Levy D, Benjamin EJ, Ho JE. Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction. Circulation. 2016 Feb 2;133(5):484-92. doi: 10.1161/CIRCULATIONAHA.115.018614. Epub 2016 Jan 8.
- Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023 Jan 18;118(17):3272-3287. doi: 10.1093/cvr/cvac013.
- Bhatnagar R, Fonarow GC, Heidenreich PA, Ziaeian B. Expenditure on Heart Failure in the United States: The Medical Expenditure Panel Survey 2009-2018. JACC Heart Fail. 2022 Aug;10(8):571-580. doi: 10.1016/j.jchf.2022.05.006. Epub 2022 Jul 6.
- Kober L, Adamo M, Ruwald AC, Tomasoni D, Anderson LJ, Andersson C, Brugts JJ, Chioncel O, Donal E, Ferdinandy P, Jhund PS, Leyva F, Lorusso R, Madigan M, Mullens W, Paolillo S, Ryan N, Simpson M, Thiele H, Thune JJ, Van Craenenbroeck EM, Van Laake LW, Verbakel M; ESC Guidelines Advisory Group. 2026 ESC Guidelines for the management of heart failure. Eur Heart J. 2026 Aug 28:ehag100. doi: 10.1093/eurheartj/ehag100. Online ahead of print. No abstract available.
- Baez-Ferrer N, Rodriguez-Cabrera CM, Parra-Esquivel PC, Burillo-Putze G, Dominguez-Rodriguez A. Prognostic Impact of Hospital Discharge After Heart Failure Admission Without Structured Heart Failure Follow-Up. J Clin Med. 2024 Dec 13;13(24):7589. doi: 10.3390/jcm13247589.
- Kwok CS, Seferovic PM, Van Spall HG, Helliwell T, Clarson L, Lawson C, Kontopantelis E, Patwala A, Duckett S, Fung E, Mallen CD, Mamas MA. Early Unplanned Readmissions After Admission to Hospital With Heart Failure. Am J Cardiol. 2019 Sep 1;124(5):736-745. doi: 10.1016/j.amjcard.2019.05.053. Epub 2019 Jun 6.
- Jansen C, Otterspoor LC, van Pol PEJ, IJff GC, Sinkeler SJ, van den Heuvel M, Jansen MEP, Scholten M, van Zutphen K, Verstappen CCAG, Hermanides N, Joosen IA, Heinen S, Valk JG, Vollenbroek-Hutten MMR, Schuuring MJ, van Hout GPJ. Structuring telemonitoring in heart failure care in The Netherlands: design and operational protocol of a nationwide initiative. Eur Heart J Digit Health. 2025 Nov 5;7(2):ztaf130. doi: 10.1093/ehjdh/ztaf130. eCollection 2026 Mar.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- Alert-HF
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .